Searching for a cure, Improving lives

Governance

The Charity is governed by 3 sets of legal organisations:  the Charity Commissions for England; the Scottish Charity Commission and, as we are a company limited by guarantee, Companies House, this means that we have to prepare an annual report for presentation to all three governing bodies.  You can find the Articles of Association – what the Charity is set up to do – here.  The rules are clear in content and timing.  This means that we have to have our Annual General meeting  within 6-months of the end of our last financial year (31 Oct) and usually results in our AGM being held in May.  This section sets out each year’s set of documentation for our annual returns.  If you can any comments, or wish to know any more about our governance, then please contact the CEO by clicking here.

 

AGM at International Conference 11/12 November 2016

Form of Proxy

AGM Agenda

Conference Agenda

 

Annual Returns 2017

Financial Returns 2016

 

Annual Returns 2016

Agenda for the AGM

Financial Report 2016

 

Annual Returns 2015  

Agenda for the AGM

Financial Returns 2015

Minutes of the AGM

 

Annual Returns 2014  

Agenda for the AGM

Financial Report 2014

Minutes of the AGM

National Meeting Slides – Tracey Davies, Diana Ribeiro

 

Annual Returns 2013  

Agenda for the AGM

Financial Report

Minutes of the AGM

 

Annual Returns 2012   

Financial Report

 

Annual Returns 2011  

Financial Report

 

Annual Returns 2010  

Financial Report

 

 

Donate

Support Action Duchenne with a monthly or one off donation

Donate

Events

View our events

View All Events

Registry

Join the DMD registry for access to clinical trials

Register

Action Duchenne launches new Research Strategy for Duchenne muscular dystrophy

November 17th, 2017

  Action Duchenne, a leading UK-wide patient and parent-led organisation for Duchenne Muscular Dystrophy, is

Tell me more

Long-term microdystrophin pre-clinical work, moving towards a potential therapy restores muscle function in canines

July 26th, 2017

Promising microdystrophin pre-clinical work, moving towards a potential therapy has shown to restore muscle function

Tell me more

FDA new approach would reduce number of patients treated with placebo

December 11th, 2017

The U.S. Food and Drug Administration (FDA) has published its recommendation for a new approach

Tell me more

Results announced from survey ‘Juggling care and daily life’

December 11th, 2017

The 17th October 2017 was an important date for the rare disease community.  The highlights of the

Tell me more

Duchenne – How do you measure a life?

Living with Duchenne – an animation

Taking charge of Duchenne

wordpress counter

Stay informed with regular updates from Action Duchenne